TY - JOUR
T1 - Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda
AU - Nakiyingi, Lydia
AU - Ssengooba, Willy
AU - Nakanjako, Damalie
AU - Armstrong, Derek
AU - Holshouser, Molly
AU - Kirenga, Bruce J.
AU - Shah, Maunank
AU - Mayanja-Kizza, Harriet
AU - Joloba, Moses L.
AU - Ellner, Jerrold J.
AU - Dorman, Susan E.
AU - Manabe, Yukari C.
N1 - Funding Information:
LN is a PhD candidate supported by by Medical Education for Equitable Services to All Ugandans a Medical Education Partnership Initiative grant number 5R24TW008886 from the Office of Global AIDS Coordinator and the U. S. Department of Health and Human Services, Health Resources and Services Administration and National Institutes of Health. The study project was supported by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services (contract number HHSN2722000900050C to “TB Clinical Diagnostics Research Consortium”). Additional support was to YCM by the Johns Hopkins University Center for AIDS Research (Grant Number 1P30AI094189 from the National Institute of Allergy and Infectious Diseases). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the government.
Publisher Copyright:
© Nakiyingi et al.
PY - 2015/2/15
Y1 - 2015/2/15
N2 - Background: Sputum smear microscopy for tuberculosis (TB) diagnosis lacks sensitivity in HIV-infected symptomatic patients and increases the likelihood that mycobacterial infections particularly disseminated TB will be missed; delays in diagnosis can be fatal. Given the duration for MTB growth in blood culture, clinical predictors of MTB bacteremia may improve early diagnosis of mycobacteremia. We describe the predictors and mortality outcome of mycobacteremia among HIV-infected sputum smear-negative presumptive TB patients in a high prevalence HIV/TB setting. Methods: Between January and November 2011, all consenting HIV-infected adults suspected to have TB (presumptive TB) were consecutively enrolled. Diagnostic assessment included sputum smear microscopy, urine Determine TB lipoarabinomannan (LAM) antigen test, mycobacterial sputum and blood cultures, chest X-ray, and CD4 cell counts in addition to clinical and socio-demographic data. Patients were followed for 12 months post-enrolment. Results: Of 394 sputum smear-negative participants [female, 63.7%; median age (IQR) 32 (28-39) years], 41/394 (10.4%) had positive mycobacterial blood cultures (mycobacteremia); all isolates were (MTB). The median CD4 cell count was significantly lower among patients with mycobacteremia when compared with those without (CD4 31 versus 122 cells/μL, p<0.001). In a multivariate analysis, male gender [OR 3.4, 95%CI (1.4-7.6), p=0.005], CD4 count <100 cells/μL [OR 3.1, 95% CI (1.1-8.6), p=0.030] and a positive lateral flow urine TB LAM antigen test [OR 15.3, 95%CI (5.7-41.1), p<0.001] were significantly associated with mycobacteremia. At 12 months of follow-up, a trend towards increased mortality was observed in patients that were MTB blood culture positive (35.3%) compared with those that were MTB blood culture negative (23.3%) (p=0.065). Conclusions: Mycobacteremia occurred in 10% of smear-negative patients and was associated with higher mortality compared with smear-negative patients without mycobacteremia. Advanced HIV disease (CD4<100 cells/mm3), male gender and positive lateral flow urine TB LAM test predicted mycobacteremia in HIV-infected smear-negative presumptive TB patients in this high prevalence TB/HIV setting.
AB - Background: Sputum smear microscopy for tuberculosis (TB) diagnosis lacks sensitivity in HIV-infected symptomatic patients and increases the likelihood that mycobacterial infections particularly disseminated TB will be missed; delays in diagnosis can be fatal. Given the duration for MTB growth in blood culture, clinical predictors of MTB bacteremia may improve early diagnosis of mycobacteremia. We describe the predictors and mortality outcome of mycobacteremia among HIV-infected sputum smear-negative presumptive TB patients in a high prevalence HIV/TB setting. Methods: Between January and November 2011, all consenting HIV-infected adults suspected to have TB (presumptive TB) were consecutively enrolled. Diagnostic assessment included sputum smear microscopy, urine Determine TB lipoarabinomannan (LAM) antigen test, mycobacterial sputum and blood cultures, chest X-ray, and CD4 cell counts in addition to clinical and socio-demographic data. Patients were followed for 12 months post-enrolment. Results: Of 394 sputum smear-negative participants [female, 63.7%; median age (IQR) 32 (28-39) years], 41/394 (10.4%) had positive mycobacterial blood cultures (mycobacteremia); all isolates were (MTB). The median CD4 cell count was significantly lower among patients with mycobacteremia when compared with those without (CD4 31 versus 122 cells/μL, p<0.001). In a multivariate analysis, male gender [OR 3.4, 95%CI (1.4-7.6), p=0.005], CD4 count <100 cells/μL [OR 3.1, 95% CI (1.1-8.6), p=0.030] and a positive lateral flow urine TB LAM antigen test [OR 15.3, 95%CI (5.7-41.1), p<0.001] were significantly associated with mycobacteremia. At 12 months of follow-up, a trend towards increased mortality was observed in patients that were MTB blood culture positive (35.3%) compared with those that were MTB blood culture negative (23.3%) (p=0.065). Conclusions: Mycobacteremia occurred in 10% of smear-negative patients and was associated with higher mortality compared with smear-negative patients without mycobacteremia. Advanced HIV disease (CD4<100 cells/mm3), male gender and positive lateral flow urine TB LAM test predicted mycobacteremia in HIV-infected smear-negative presumptive TB patients in this high prevalence TB/HIV setting.
KW - Bacteremia
KW - HIV
KW - LAM
KW - Mortality
KW - Mycobacterial infections
KW - Predictors
KW - Smear- negative
KW - Sub-Saharan Africa
UR - http://www.scopus.com/inward/record.url?scp=84924061407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924061407&partnerID=8YFLogxK
U2 - 10.1186/s12879-015-0812-4
DO - 10.1186/s12879-015-0812-4
M3 - Article
C2 - 25888317
AN - SCOPUS:84924061407
VL - 15
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
SN - 1471-2334
IS - 1
M1 - 62
ER -